-+ 0.00%
-+ 0.00%
-+ 0.00%

Olema reports initial Phase 1 data for OP-3136 KAT6 inhibitor in solid tumors

PUBT·05/21/2026 21:02:17
Listen to the news
Olema reports initial Phase 1 data for OP-3136 KAT6 inhibitor in solid tumors
  • Olema Pharmaceuticals disclosed preliminary Phase 1 data for OP-3136, an oral KAT6 inhibitor, with results scheduled for presentation on May 30, 2026 at the ASCO annual meeting.
  • The early readout showed the drug was generally tolerable in heavily pretreated patients, with no study-stopping safety signal reported.
  • Initial activity was observed across several advanced solid tumor types, supporting continued dose expansion and further development.
  • The program is moving forward with OP-3136 as a standalone therapy, with combination testing planned with fulvestrant or palazestrant in ER+/HER2- advanced breast cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211700PRIMZONEFULLFEED9724828) on May 21, 2026, and is solely responsible for the information contained therein.